Oppenheimer Maintains Outperform on Boston Scientific, Lowers Price Target to $85

Benzinga Newsdesk www.benzinga.com Negative 94.1%

Neg 94.1% Neu 0% Pos 0%

Oppenheimer analyst Suraj Kalia maintains Boston Scientific (NYSE:BSX) with a Outperform and lowers the price target from $90 to $85.